ArticleTechnology in cancer research & treatment2018
High-Frequency Irreversible Electroporation for Intracranial Meningioma: A Feasibility Study in a Spontaneous Canine Tumor Model.
Article in Technology in cancer research & treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 91 citations in OpenAlex.
- Neuromodulation in Neuro-Oncology: A Scoping Review.Journal of personalized medicine · 2026Review
- Translational insights into canine dorsal root ganglia cell types using cross-species comparisons.bioRxiv : the preprint server for biology · 2026Article
- Dose Is a Critical Factor Affecting Treatment Volumes for Integrated Nanosecond Pulse Irreversible Electroporation (INSPIRE).IEEE transactions on bio-medical engineering · 2026Article
- Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications.Biomaterials research · 2026Review
- Invasive properties of patient-derived glioblastoma cells after reversible electroporationRadiology and oncology · 2025Article
- Article
- Impact of Voltage on the Production on Spherical Ablations for Integrated Time Nanosecond Pulse Irreversible Electroporation.Bioelectricity · 2025Article
- Canine organoids: state-of-the-art, translation potential for human medicine and plea for standardization.Frontiers in veterinary science · 2025Review
- Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma.Communications materials · 2025Review
- Tumor-derived extracellular vesicles disrupt the blood-brain barrier endothelium following high-frequency irreversible electroporation.Scientific reports · 2024Article
- Investigation of High Frequency Irreversible Electroporation for Canine Spontaneous Primary Lung Tumor Ablation.Biomedicines · 2024Article
- Electroporation in Translational Medicine: From Veterinary Experience to Human Oncology.Cancers · 2024Review
- Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024Review
- Domestic Animal Models of Central Nervous System Tumors: Focus on Meningiomas.Life (Basel, Switzerland) · 2023Review
- BBB opening by low pulsed electric fields, depicted by delayed-contrast MRI, enables efficient delivery of therapeutic doxorubicin doses into mice brains.Fluids and barriers of the CNS · 2023Article
- Control of the Electroporation Efficiency of Nanosecond Pulses by Swinging the Electric Field Vector Direction.International journal of molecular sciences · 2023Article
- Development of a Synthetic, Injectable Hydrogel to Capture Residual Glioblastoma and Glioblastoma Stem-Like Cells with CXCL12-Mediated Chemotaxis.Advanced healthcare materials · 2023Article
- High-frequency irreversible electroporation improves survival and immune cell infiltration in rodents with malignant gliomas.Frontiers in oncology · 2023Article
- High-frequency irreversible electroporation brain tumor ablation: exploring the dynamics of cell death and recovery.Bioelectrochemistry (Amsterdam, Netherlands) · 2022Article
- Advancements in drug delivery methods for the treatment of brain disease.Frontiers in veterinary science · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-frequency irreversible electroporation is a nonthermal method of tissue ablation that uses bursts of 0.5- to 2.0-microsecond bipolar electric pulses to permeabilize cell membranes and induce cell death. High-frequency irreversible electroporation has potential advantages for use in neurosurgery, including the ability to deliver pulses without inducing muscle contraction, inherent selectivity against malignant cells, and the capability of simultaneously opening the blood-brain barrier surrounding regions of ablation. Our objective was to determine whether high-frequency irreversible electroporation pulses capable of tumor ablation could be delivered to dogs with intracranial meningiomas. Three dogs with intracranial meningiomas were treated. Patient-specific treatment plans were generated using magnetic resonance imaging-based tissue segmentation, volumetric meshing, and finite element modeling. Following tumor biopsy, high-frequency irreversible electroporation pulses were stereotactically delivered in situ followed by tumor resection and morphologic and volumetric assessments of ablations. Clinical evaluations of treatment included pre- and posttreatment clinical, laboratory, and magnetic resonance imaging examinations and adverse event monitoring for 2 weeks posttreatment. High-frequency irreversible electroporation pulses were administered successfully in all patients. No adverse events directly attributable to high-frequency irreversible electroporation were observed. Individual ablations resulted in volumes of tumor necrosis ranging from 0.25 to 1.29 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.